Table 2. Selected outcomes of... | American Society of Hematology

Table 2.

Selected outcomes of monotherapy azacitidine or decitabine (n > 75 patients)

Trial	CALGB 9221	NCT01522976	NCT00071799	NCT00102687	NCT02158936	NCT01751867	NCT00260065	NCT00043381	NCT00067808	NCT00043134	NCT01041846
Drug	Azacitidine	Azacitidine	Azacitidine	Azacitidine	Azacitidine	Decitabine	Decitabine	Decitabine	Decitabine	Decitabine	Decitabine
N	99	92	179	151	177	132	99	89	95	119	103
IPSS
Low	2	3	0				1
INT-1	21	25	5		61	57	52	28	19	8	52
INT-2	9	40	76		83	58	23	38	26	64	35
High	7	20	82		33	20	23	23	11	46	13
Cytogenetic risk
Good		29	83		81		49			38	65
Intermediate		16	37		22		15			9	15
Poor		33	50		32		29			57	19
MDS subtype
MDS SLD	17		0	65		27	20	12		5	4
MDS RS	5		0	21		4	17	7		3
MDS MLD			0								27
LB MDS	22		0	86		31	37	19		8	31
MDS EB1		29	14				10		23	30	26
MDS EB2		35	98				31		30	31	32
MDS-EB	32	64	112	45		85	41	47	53	61	58
Unspecified MDS	1	10							19
AML	37		55	4		11	10	17	5	41
CMML	7	18	11	16		8	11	6	18		11
Reported responses
CR	7	22	30	6	26	13	17	8	32	16	13
PR	16	0	21	5			0	7	1	7	1
mCR		11			36	22	15		10		23
HI	37	13	87/177	73/151	59/177	50	18	12	13	18	19
HI-E	13		62/157	58/130				7			35/97
HI-P	20		46/141	23/54				7			30/69
HI-N	16		25/131	17/70				3			20/53
RBC TI	29/65		50/111	40/71		38/88	22/66
OS	20 mo	15 mo	24.5 mo			23.8 mo	19.4 mo	23.5 mo	19 mo	10.1mo	17.7mo

Trial	CALGB 9221	NCT01522976	NCT00071799	NCT00102687	NCT02158936	NCT01751867	NCT00260065	NCT00043381	NCT00067808	NCT00043134	NCT01041846
Drug	Azacitidine	Azacitidine	Azacitidine	Azacitidine	Azacitidine	Decitabine	Decitabine	Decitabine	Decitabine	Decitabine	Decitabine
N	99	92	179	151	177	132	99	89	95	119	103
IPSS
Low	2	3	0				1
INT-1	21	25	5		61	57	52	28	19	8	52
INT-2	9	40	76		83	58	23	38	26	64	35
High	7	20	82		33	20	23	23	11	46	13
Cytogenetic risk
Good		29	83		81		49			38	65
Intermediate		16	37		22		15			9	15
Poor		33	50		32		29			57	19
MDS subtype
MDS SLD	17		0	65		27	20	12		5	4
MDS RS	5		0	21		4	17	7		3
MDS MLD			0								27
LB MDS	22		0	86		31	37	19		8	31
MDS EB1		29	14				10		23	30	26
MDS EB2		35	98				31		30	31	32
MDS-EB	32	64	112	45		85	41	47	53	61	58
Unspecified MDS	1	10							19
AML	37		55	4		11	10	17	5	41
CMML	7	18	11	16		8	11	6	18		11
Reported responses
CR	7	22	30	6	26	13	17	8	32	16	13
PR	16	0	21	5			0	7	1	7	1
mCR		11			36	22	15		10		23
HI	37	13	87/177	73/151	59/177	50	18	12	13	18	19
HI-E	13		62/157	58/130				7			35/97
HI-P	20		46/141	23/54				7			30/69
HI-N	16		25/131	17/70				3			20/53
RBC TI	29/65		50/111	40/71		38/88	22/66
OS	20 mo	15 mo	24.5 mo			23.8 mo	19.4 mo	23.5 mo	19 mo	10.1mo	17.7mo

HI-E, Hematologic improvement - erythroid; HI-N, hematologic improvement - neutrophils; HI-P, hematologic improvement - platelets; MLD, multilineage dysplasia; RBC TI, red blood cell transfusion independence; RS, ring sideroblasts; SLD, single lineage dysplasia.

View Large

This Feature Is Available To Subscribers Only